Unprecedented PFS Improvement in Relapsed Multiple Myeloma

(MedPage Today) -- Progression-free survival (PFS) in relapsed multiple myeloma almost doubled with the addition of the CD38 inhibitor isatuximab (Sarclisa) to a standard proteasome inhibitor (PI) regimen, according to long-term follow-up from...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news